SCHEMBL5399472

SCHEMBL5399472

CCOC(=O)c1[nH]c2ccc(C)cc2c1C=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.67
KDM4E B2RXH2 8/20 0.67
MAPT P10636 4/20 0.67
GAA P10253 3/20 0.67
RAB9A P51151 3/20 0.67
NPC1 O15118 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
TP53 P04637 1/20 0.67
ALOX15 P16050 1/20 0.65
KMT2A Q03164 2/20 0.59
TSHR P16473 1/20 0.57
HPGD P15428 7/20 0.52
HSD17B10 Q99714 5/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CYP1A2 P05177 1/20 0.47
XBP1 P17861 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9260498 0.89 ALOX15 (0.77) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL15331909 0.88 ALOX15 (0.64) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL29952885 0.87 ALOX15 (0.62) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL333829 0.87 ALOX15 (0.62) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL1503856 0.87 ALOX15 (0.81) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL29954955 0.87 ALOX15 (0.81) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL3275793 0.87 ALOX15 (0.62) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL5392425 0.86 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL37221912 0.86 ALDH1A1 (0.73) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL7250379 0.86 ALDH1A1 (0.73) ALDH1A1KDM4EMAPTGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
US-7217729-B2 Substituted indoles, process for the production thereof and use thereof for combatting pain GRUNENTHAL GMBH (DE) 2007-05-15 US disclosed
US-20040225003-A1 4,6-Dimethyl-3-{[3'-(N,N-dimethylaminomethyl)-4-hydroxy-4'-(3''-methoxyphenyl)-cyclohexylamino]-methyl}-1H-indole 2-carboxylic acid ethyl ester or other derivatives of substituted indoles; for treatment or prevention of neurodegenerative diseases, psychological disorders, AIDS, inflammation or allergies GRUNENTHAL GMBH (DE) 2004-11-11 US disclosed
US-5428043-A Tricyclic-cyclic amines as novel cholinesterase inhibitors PFIZER INC. (US) 1995-06-27 US disclosed
EP-0441517-A2 Tricyclic amines as novel cholinesterase inhibitors PFIZER INC. (US) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225003-A1 4,6-Dimethyl-3-{[3'-(N,N-dimethylaminomethyl)-4-hydroxy-4'-(3''-methoxyphenyl)-cyclohexylamino]-methyl}-1H-indole 2-carboxylic acid ethyl ester or other derivatives of substituted indoles; for treatment or prevention of neurodegenerative diseases, psychological disorders, AIDS, inflammation or allergies HNMT, HTR6, HTR3C ALDH1A1 1253/4885KDM4E 290/4885MAPT 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.